Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 25;10(1):8609.
doi: 10.1038/s41598-020-65029-6.

Effect of 5-year continuous positive airway pressure treatment on MMPs and TIMPs: implications for OSA comorbidities

Affiliations

Effect of 5-year continuous positive airway pressure treatment on MMPs and TIMPs: implications for OSA comorbidities

Beatrix Simon et al. Sci Rep. .

Abstract

Continuous positive airway pressure (CPAP) treatment results in nearly complete remission of symptoms of obstructive sleep apnoea (OSA); however, its effect on OSA comorbidities including cardiovascular diseases remains contradictory. Here we investigated the short- and long-term effect of CPAP treatment on matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in patients with severe OSA. Serum levels of 7 MMPs and 3 TIMPs were followed in OSA patients (n = 28) with an apnoea-hypopnoea index of ≥30 events/h at the time of diagnosis and at control visits (2 months, 6 months and 5 years) after initiation of fixed-pressure CPAP treatment. The first few months of CPAP therapy resulted in significant decrease of MMP-8 and MMP-9 levels (MMP-8: 146 (79-237) vs. 287 (170-560) pg/mL; MMP-9: 10.1 (7.1-14.1) vs. 12.7 (10.4-15.6) ng/mL, p < 0.05 for each at 2 months), while the rest of the panel remained unchanged as compared to baseline values. In contrast, at 5 years, despite of uninterrupted CPAP treatment and excellent adherence the levels of MMP-8, MMP-9 and TIMPs significantly increased (p < 0.05). Our data suggest that initiation of CPAP therapy leads to a decrease in the level of key MMPs in the short-term; however, this effect is not sustained over the long-term.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Study flow chart. OSA: obstructive sleep apnoea, CPAP: continuous positive airway pressure, AHI: apnoea-hypopnoea index, PaCO2: arterial carbon dioxide tension.
Figure 2
Figure 2
Serum MMP (Panel A–F) and TIMP (Panel G–I) levels of study subjects during the 5-year follow-up. Marker levels were assessed at the time of diagnosis (OSA), at 2 and 6 months (2M and 6M) and at 5 years of CPAP therapy (5Y). OSAS: obstructive sleep apnoea syndrome (baseline visit), CPAP: continuous positive airway pressure, MMP: matrix metalloproteinase, TIMP: tissue inhibitor of matrix metalloproteinase. Standard box plots with median (25th and 75th percentiles) and whiskers (at minimum and maximum values) are shown. *p < 0.05 vs. baseline visit; #p < 0.05 and ###p < 0.001 vs. 2-month visit; °p < 0.05 and °°°p < 0.001 vs. 6-month visit.

References

    1. Eisele HJ, Markart P, Schulz R. Obstructive sleep apnea, oxidative stress, and cardiovascular disease: evidence from human studies. Oxid. Med. Cell. Longev. 2015;2015:608438. doi: 10.1155/2015/608438. - DOI - PMC - PubMed
    1. Bradley TD, Floras JS. Obstructive sleep apnoea and its cardiovascular consequences. Lancet. 2009;373:82–93. doi: 10.1016/S0140-6736(08)61622-0. - DOI - PubMed
    1. Johnson JL. Metalloproteinases in atherosclerosis. Eur. J. Pharmacol. 2017;816:93–106. doi: 10.1016/j.ejphar.2017.09.007. - DOI - PubMed
    1. Myasoedova VA, Chistiakov DA, Grechko AV, Orekhov AN. Matrix metalloproteinases in pro-atherosclerotic arterial remodeling. J. Mol. Cell. Cardiol. 2018;123:159–167. doi: 10.1016/j.yjmcc.2018.08.026. - DOI - PubMed
    1. Tan CH, et al. Associations of matrix metalloproteinase-9 and monocyte chemoattractant protein-1 concentrations with carotid atherosclerosis, based on measurements of plaque and intima-media thickness. Atherosclerosis. 2014;232:199–203. doi: 10.1016/j.atherosclerosis.2013.11.040. - DOI - PubMed

Publication types

Substances